SCHEMBL6330358

SCHEMBL6330358

CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(Cc3ncc[nH]3)CC2)cc1

nearest known ligand 0.85

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 15/20 0.85
OPRM1 P35372 14/20 0.85
OPRK1 P41145 13/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325543 0.89 OPRM1 (0.85) OPRD1OPRM1OPRK1
SCHEMBL5488273 0.88 OPRD1 (0.72) OPRD1OPRM1OPRK1
SCHEMBL6175709 0.83 OPRM1 (0.82) OPRD1OPRM1OPRK1
SCHEMBL6334645 0.82 OPRD1 (0.85) OPRD1OPRM1OPRK1
SCHEMBL6329556 0.81 OPRD1 (0.88) OPRD1OPRM1OPRK1
SCHEMBL6336091 0.81 OPRD1 (0.85) OPRD1OPRM1OPRK1
SCHEMBL6332701 0.80 OPRD1 (0.85) OPRD1OPRM1OPRK1
SCHEMBL6334423 0.79 OPRM1 (0.67) OPRD1OPRM1OPRK1
SCHEMBL5879360 0.79 OPRD1 (0.57) OPRD1OPRM1OPRK1
SCHEMBL5879364 0.79 OPRD1 (0.62) OPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875777-B2 Compounds ASTRAZENECA AB (SE) 2005-04-05 US disclosed
EP-1242406-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-03-17 EP disclosed
US-20030036552-A1 Novel compounds ASTRAZENECA AB (SE) 2003-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030036552-A1 Novel compounds ARRB1, OPRK1, OPRM1 OPRD1 4/4885OPRM1 3/4885OPRK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.